Synthesis of new series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4-ones for their bacterial and cyclin-dependent kinases (CDKs) inhibitory activities

Medicinal Chemistry Research

Volumn 20, Issue 4, 2011, Pages 408-420

  Geffken, Detlef ^a   Soliman, Raafat ^b   Soliman, Farid S D ^b   Abdel Khalek, Magdi M ^b   Issa, Doaa A E ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Antibacterial activity; Hydrazono pyridazine; Pyrazole; Pyrazolo 4,3 d pyrimidin 7 one; Pyrido 2,3 d pyrimidin 4 one

Indexed keywords

2 (2 ETHOXYPHENYL 5 PHENYLPIPERAZINOSULFONAMIDO) 3H PYRIDO [2,3 D]PYRIMIDIN 4 ONE; 6 PHENYL 5 PHENYLHYDRAZONO 2,3,4,5 TETRAHYDROPYRIDAZINE 3,4 DIONE; ANTIINFECTIVE AGENT; CYCLIN DEPENDENT KINASE; PYRAZOLO[4,3 D]PYRIMIDIN 7(6H) ONE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDIN 4(3H) ONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 80051985952     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9328-z     Document Type: Article

References (33)

1. Althuis TH, Moore PF, Hess HJ (1979) Development of ethyl 3, 4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity. J Med Chem 22(1): 44-48 (Pubitemid 9082477)
2. Bell AS, Brown D, Terrett NK (1992) Pyrazolopyrimidinone antianginal agents. European patent application EP 0463 756 A1.
3. Braga R, Hecquet L, Blonski C (2004) Slow-binding inhibition of 2-keto-3-deoxy-6-phosphogluconate (KDPG) aldolase. Bioorg Med Chem 12:2965-2972 (Pubitemid 38622130)
4. Burch HA, Gray JE (1972) Acylpyruvates as potential antifungal agents. J Med Chem 15(4):429-431
5. Dabiri M, Arvin-Nezhad H, Khavasi HR, Bazgir A (2007) A novel and efficient synthesis of pyrimido[4,5-d]pyrimidine-2,4,7-trione and pyrido[2,3-d:6, 5-d]dipyrimidine-2,4,6,8-tetrone derivatives. Tetrahedron 63:1770-1774 (Pubitemid 46107538)
6. Dreyer MK, Borcherding DR, Dumont JA, Peet NP, Tsay JT, Wright PS, Bitonti AJ, Shen J, Kim S-H (1998) Crystal structure of human cyclin-dependent kinase 2 in complex with the adeninederived inhibitor H717. J Med Chem 44:524-530
7. Fadnavis NW, Radhika KR (2004) Enantio- and regiospecific reduction of ethyl 4-phenyl-2,4-dioxobutyrate with baker's yeast: preparation of (R)-HPB ester. Tetrahedron Asymmetr 15:3443-3447 (Pubitemid 39446789)
8. Gardner TS, Wenis E, Lee J (1961) Synthesis of 5-substituted 3-isoxazolecarboxylic acid hydraides and derivatives. J Org Chem 26:1514-1518
9. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538 (Pubitemid 28357362)
10. Haesselein JL, Jullian N (2002) Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr Top Med Chem 2(9):1037-1050
11. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M (1997) Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40(4):408-412 (Pubitemid 27080019)
12. Hecht SM, Bock RM, Schmitz RY, Skoog F, Leonard N (1971) Cytokinins: development of a potent antagonist. J Proc Natl Acad Sci USA 68(10):2608-2610
13. Jain SR, Kar A (1971) Antibacterial activity of some essential oils and their combinations. Planta Med 20:118-123
14. ′ sulfonamide moiety of a phenyl ring. Bioorg Med Chem 9(11): 3013-3021
15. Kim D-K, Lee JY, Park H-J, Thai KM (2004) Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5′-sulfonamide moiety of phenyl ring. Bioorg Med Chem Lett 14(9):2099-2103 (Pubitemid 38481369)
16. Krystof V, Lenobel R, Vavlicek L, Kuzma M, Strnad M (2002) Synthesis and biological activity of olomoucine II. Bioorg Med Chem Lett 12:3283-3286 (Pubitemid 35251910)
17. Liu BB (2004) New compounds for treating impotence. European patent application EP 1 400 522 A1
18. Marvel CS, Dreger EE (1941) In: Blatt AH (ed) Organic syntheses collect, vol 1. Wiley, New York, NY, pp 238-240
19. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of R-roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527-536 (Pubitemid 27060443)
20. Mitchell A (1979) Spectroscopic studies of tautomeric systems-III. Tetrahedron 35(17):2013-2019
21. Mohamed NR, El-Saidi MMT, Ali YM, Elnagdi MH (2007) Utility of 6-amino-2-thiouracil as a precursor for the synthesis of bioactive pyrimidine derivatives. Bioorg Med Chem 15:6227-6235 (Pubitemid 47088954)
22. Moravcova D, Krystof V, Havlicek L, Moravec J, Lenobel R, Strnad M (2003) Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 13:2989-2992 (Pubitemid 37009743)
23. Moravec J, Krystof V, Hanus J, Havlicek L, Moravcova D, Fuksova K, Kuzma M, Lenobel R, Otyepka M, Strand M (2003) 2,6,8,9- Tetrasubstituted purines as new CDK1 inhibitors. Bioorg Med Chem Lett 13:2993-2996 (Pubitemid 37020870)
24. Piazza GA, Pamukcu R (2000) Preparation of pyridopyrimidinones, pyrimidopyrimidinones, pyrimidotriazones and related compounds for the treatment of precancerous lesions. U.S. Patent. U.S. 6060477
25. Purcell WP, Gilliom RD, Parish HA (1982) Pyridopirimidone derivatives. U.S. Patent. U.S. 4 361 700
26. Ravi Kanth S, Venkat Reddy G, Hara Kishore K, Shanthan Rao P, Narsaiah B, Surya Narayana Murthy U (2006) Convenient synthesis of novel 4-substitutedamino-5-trifluoromethyl-2,7- disubstituted pyrido[2,3-d]pyrimidines and their antibacterial activity. Eur J Med Chem 41:1011-1016
27. Roy AK, Batra S (2003) Facile Baylis-Hillman reaction of substituted 3-isoxazolecarbaldehydes: the impact of a proximal heteroatom within a heterocycle on the acceleration of the reactions. Synthesis 15:2325-2330 (Pubitemid 37409976)
28. Scott AC (1989) Mackie and MacCarteny practical medical microbiology. In: Collee JG, Duguid JP, Frazer AG, Marmion BP (eds) Laboratory control of antimicrobial therapy, 13th edn, vol 2. Churchil Livingstone, New York, p 161
29. Taylor EC, Crovetti AJ (1954) Pyridine-1-oxides. I. Synthesis of some nicotinic acid derivatives. J Org Chem 19(10):1633-1640
30. van Herk T, Brussee J, van den Nieuwendijk AMCH, van der Klein PAM, IJzerman AP, Stannek C, Burmeister A, Lorenzen A (2003) Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem 46:3945-3951 (Pubitemid 37034143)
31. Veselý J, Havlicek L, Strnad M, Blow J, Donella-Deana A, Pinna L, Letham S, Kato J, Detivaud L, LeClerc S, Meijer L (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224(2):771-786 (Pubitemid 24282865)
32. Walford GL, Jones H, Shen TY (1971) Aza analogs of 5-(pfluorophenyl) salicylic acid. J Med Chem 14(4):339-344
33. Zalesov VV, Kataev SS, Pulina NA, Kovylyaeva NV (2002) 4-Aryl- 2,4-dioxobutanoic acids and their derivatives in reactions with diazoalkanes. Russ J Org Chem 38(6):840-844 (Pubitemid 37116754)